Toripalimab

Toripalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Toripalimab is a humanized monoclonal antibody that targets programmed death receptor 1 (PD-1). It is used to treat patients with unresectable or metastatic melanoma who have previously failed systemic therapy. It is intended for treatment Breast cancer, lymphoma, malignant melanoma, genitourinary system cancer and other types of solid tumors.

Target	PDCD1/PD1/CD279
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1924598-82-2
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on PDCD1/PD1/CD279

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue